Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ripretinib - Deciphera Pharmaceuticals

Drug Profile

Ripretinib - Deciphera Pharmaceuticals

Alternative Names: DCC-2618; QINLOCK

Latest Information Update: 14 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Developer Deciphera Pharmaceuticals; Specialised Therapeutics Asia; ZAI Lab
  • Class Amines; Antineoplastics; Bromobenzenes; Cyclopropanes; Fluorinated hydrocarbons; Naphthyridines; Phenylurea compounds; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein b-raf inhibitors; Proto-oncogene protein c-kit expression inhibitors; TIE-2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Glioblastoma; Anaplastic astrocytoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Gastrointestinal stromal tumours
  • Phase I Solid tumours; Systemic mastocytosis
  • No development reported Glioblastoma

Most Recent Events

  • 11 Jun 2024 Deciphera Pharmaceuticals has been acquired by Ono Pharmaceutical
  • 31 Jan 2024 Deciphera Pharmaceuticals has patent protection for ripretinib in Europe, Australia, South America, and Asia
  • 18 Jan 2024 Adverse events data from a phase III INTRIGUE trial in Gastrointestinal stromal tumours presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top